Basit öğe kaydını göster

Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.

dc.contributor.authorTurk, Haci M.
dc.contributor.authorRietschel, Petra
dc.contributor.authorBentsion, Dmitry
dc.contributor.authorCicin, Irfan
dc.contributor.authorGogishvili, Miranda
dc.contributor.authorGullo, Giuseppe
dc.contributor.authorOzguroglu, Mustafa
dc.contributor.authorSezer, Ahmet
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorGumus, Mahmut
dc.contributor.authorBondarenko, Igor
dc.contributor.authorLowy, Israel
dc.contributor.authorSeebach, Frank A.
dc.contributor.authorLee, Sue
dc.contributor.authorPouliot, Jean-Francois
dc.contributor.authorMcGinniss, Jennifer
dc.contributor.authorRizvi, Naiyer A.
dc.contributor.authorSriuranpong, Virote
dc.contributor.authorClingan, Philip R.
dc.contributor.authorGladkov, Oleg
dc.date.accessioned2021-12-10T09:49:34Z
dc.date.available2021-12-10T09:49:34Z
dc.date.issued2021
dc.identifier.citationOzguroglu M., Sezer A., Kilickap S., Gumus M., Bondarenko I., Gogishvili M., Turk H. M. , Cicin I., Bentsion D., Gladkov O., et al., "Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.", JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021
dc.identifier.issn0732-183X
dc.identifier.otherav_14f44025-8fbb-4351-aa07-8eb5879f5e2a
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/168557
dc.identifier.urihttps://doi.org/10.1200/jco.2021.39.15_suppl.9085
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectOnkoloji
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectSağlık Bilimleri
dc.subjectHealth Sciences
dc.subjectOncology
dc.titleCemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.
dc.typeMakale
dc.relation.journalJOURNAL OF CLINICAL ONCOLOGY
dc.contributor.departmentİstanbul Üniversitesi , Cerrahpaşa Tıp Fakültesi , Dahili Bilimler
dc.identifier.volume39
dc.identifier.issue15
dc.contributor.firstauthorID2770001


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster